$0.84 EPS Expected for Abbott Laboratories (NYSE:ABT) This Quarter

Equities analysts expect Abbott Laboratories (NYSE:ABT) to report earnings per share of $0.84 for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Abbott Laboratories’ earnings, with estimates ranging from $0.83 to $0.86. Abbott Laboratories posted earnings per share of $0.75 during the same quarter last year, which would indicate a positive year-over-year growth rate of 12%. The company is scheduled to report its next quarterly earnings results on Wednesday, October 16th.

On average, analysts expect that Abbott Laboratories will report full-year earnings of $3.24 per share for the current fiscal year, with EPS estimates ranging from $3.22 to $3.25. For the next fiscal year, analysts anticipate that the firm will post earnings of $3.63 per share, with EPS estimates ranging from $3.60 to $3.68. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, July 17th. The healthcare product maker reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.80 by $0.02. The firm had revenue of $7.98 billion for the quarter, compared to analyst estimates of $8 billion. Abbott Laboratories had a return on equity of 17.39% and a net margin of 9.36%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period last year, the company earned $0.73 EPS.

A number of equities research analysts have recently weighed in on ABT shares. Cowen lifted their price objective on Abbott Laboratories from $86.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, July 18th. William Blair reiterated an “outperform” rating on shares of Abbott Laboratories in a research report on Thursday, April 18th. BMO Capital Markets lifted their price target on Abbott Laboratories from $87.00 to $94.00 and gave the company an “outperform” rating in a research report on Thursday, July 18th. Royal Bank of Canada lifted their price target on Abbott Laboratories to $82.00 and gave the company a “buy” rating in a research report on Monday, April 15th. They noted that the move was a valuation call. Finally, Bank of America restated a “buy” rating and set a $81.00 price target on shares of Abbott Laboratories in a research report on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $85.82.

In other Abbott Laboratories news, Director Sally E. Blount sold 2,500 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $87.65, for a total value of $219,125.00. Following the sale, the director now directly owns 26,266 shares of the company’s stock, valued at $2,302,214.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 7,269 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $82.00, for a total value of $596,058.00. Following the completion of the sale, the executive vice president now directly owns 99,479 shares in the company, valued at $8,157,278. The disclosure for this sale can be found here. Insiders have sold 818,331 shares of company stock worth $65,369,215 over the last 90 days. 0.70% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Manchester Financial Inc. purchased a new position in shares of Abbott Laboratories in the second quarter worth $30,000. Front Row Advisors LLC raised its stake in shares of Abbott Laboratories by 790.9% in the first quarter. Front Row Advisors LLC now owns 392 shares of the healthcare product maker’s stock worth $31,000 after purchasing an additional 348 shares during the last quarter. Weaver Consulting Group purchased a new position in shares of Abbott Laboratories in the first quarter worth $33,000. Beacon Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the first quarter worth $38,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Abbott Laboratories in the second quarter worth $42,000. 73.42% of the stock is currently owned by institutional investors and hedge funds.

Shares of ABT stock traded down $0.26 during trading hours on Friday, reaching $85.82. The company’s stock had a trading volume of 4,756,375 shares, compared to its average volume of 4,637,468. The company has a market capitalization of $153.66 billion, a PE ratio of 29.80, a P/E/G ratio of 2.45 and a beta of 1.12. Abbott Laboratories has a one year low of $63.07 and a one year high of $88.76. The business’s fifty day moving average is $85.32. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.58 and a quick ratio of 1.13.

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Monday, July 15th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, July 12th. This represents a $1.28 annualized dividend and a dividend yield of 1.49%. Abbott Laboratories’s dividend payout ratio is presently 44.44%.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Featured Story: What is the Quick Ratio?

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.